Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
7.61 USD -1.55% Intraday chart for Maravai LifeSciences Holdings, Inc. -11.41% +16.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego MT
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating MT
Transcript : Maravai LifeSciences Holdings, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 02:15 PM
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care MT
Maravai LifeSciences Shares Surge After Price Target Raises, Q4 Beat MT
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating MT
Stifel Trims Price Target on Maravai LifeSciences to $10 From $11, Maintains Buy Rating MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell MT
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating MT
Top Premarket Gainers MT
Maravai LifeSciences' Q4 Adjusted Earnings, Revenue Decline MT
Transcript : Maravai LifeSciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q4 Revenue $74.1M, vs. Street Est of $64.3M MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Posts Q4 EPS $0.01, vs. Street Est of $-0.01 MT
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay MT
North American Morning Briefing : Traders Await -2- DJ
BofA Securities Upgrades Maravai LifeSciences to Buy From Neutral MT
Chart Maravai LifeSciences Holdings, Inc.
More charts
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
7.73 USD
Average target price
9.785 USD
Spread / Average Target
+26.58%
Consensus
  1. Stock Market
  2. Equities
  3. MRVI Stock
  4. News Maravai LifeSciences Holdings, Inc.
  5. Sector Update: Health Care Stocks Advance Friday Afternoon